The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.

Authors

Kohei Hashimoto, Kouji Izumi, Takashi Shima, Yuki Kato, Koji Mita, Takehiko Okamura, Shogo Inoue, Shuichi Tatarano, Nobumichi Tanaka, Noriyasu Kawai, Manabu Kamiyama, Ippei Chikazawa, Seiji Hoshi, Takashi Fukagai, Kazuyoshi Shigehara, Shizuko Takahara, Atsushi Mizokami

Published in

The Prostate. Jul 02, 2026. Epub Jul 02, 2026.

Abstract

This study aimed to clarify whether variations in the lowest prostate‑specific antigen (PSA) level prior to the development of castration‑resistant prostate cancer (CRPC) influence the efficacy of subsequent enzalutamide (ENZ) or abiraterone plus prednisolone (ABI) therapy in metastatic CRPC.
Using data from the ENABLE study, an investigator‑initiated, multicenter, randomized controlled trial, patients were retrospectively categorized into two groups based on the lowest PSA level prior to metastatic CRPC development: ≤ 0.05 ng/mL (low group) and > 0.05 ng/mL (high group). Endpoints included time to PSA progression (TTPP), radiographic progression‑free survival (rPFS), docetaxel‑free survival (DFS), and overall survival (OS) in the overall study population and within the ABI and ENZ treatment arms.
A total of 39 and 94 patients were classified into the low and high groups, respectively. In the overall population, survival outcomes did not differ significantly between the groups except for DFS (median 29.0 vs. 15.2 months, p = 0.0209). In the ABI arm (low group, n = 15; high group, n = 45), median TTPP, rPFS, DFS, and OS were undefined versus 4.7 months, 39.5 versus 9.8 months, 29.0 versus 14.0 months, and undefined versus 33.3 months in the low and high groups, respectively (p = 0.0443, p = 0.0243 p = 0.0106, and p = 0.0319). In contrast, in the ENZ arm (low group, n = 24; high group, n = 49), no significant differences were observed in any endpoint between the two groups.
The findings of this study indicate that the lowest PSA level prior to CRPC onset may have a potential association with outcomes following subsequent ABI therapy, whereas no such trend was observed for ENZ in metastatic CRPC.

PMID:
42391446
Bibliographic data and abstract were imported from PubMed on 03 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.